REFERENCES
- Wilson PD. Polycystic kidney disease. N Engl J Med. 2004;350:151–164.
- Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med. 1993;329:332–342.
- Ecder T, Edelstein CL, Chapman AB, Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999;14:1113–1116.
- Nutahara K, Higashihara E, Horie S, Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2005;99:18–23.
- Wołyniec W, Jankowska MM, Król E, Czarniak P, Rutkowski B. Current diagnostic evaluation of autosomal dominant polycystic kidney disease. Pol Arch Med Wewn. 2008;118:767–773.
- Devereux RB, Alonso DR, Lutas EM, Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450–458.
- Ruggenenti P, Perna A, Mosconi L, Randomized placebo-controlled trial of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–1863.
- Yusuf S. Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study. Eur Heart J. 2001;22:103–104.
- Dahlof B, Devereux RB, Kjeldsen SE, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002;359:995–1003.
- Ecder T, Chapman AB, Brosnahan GM, Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35:427–432.
- Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003;63:678–685.
- Watson ML, Macnicol AM, Allan PL, Wright AF. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int. 1992;41:206–210.
- Levey AS, Greene T, Beck GJ, Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol. 1999;10:2426–2439.
- Valero FA, Martinez-Vea A, Bardaji A, Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1999;10:1020–1026.
- Martinez-Vea A, Bardaj A, Gutierrez C, Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: A prehypertensive state. Am J Kidney Dis. 2004;44:216–223.
- Oflaz H, Alisir S, Buyukaydin B, Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68:2244–2249.
- Ecder T, McFann KK, Raynolds MV, Schrier RW. No effect of angiotensin-converting enzyme gene polymorphism on disease progression and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Am J Nephrol. 2003;23:466–470.
- Schrier R, McFann K, Johnson A, Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002;13:1733–1739.